Construction of a clinical survival prognostic model for middle-aged and elderly patients with stage III rectal adenocarcinoma

Table 1 Baseline demographic and clinical characteristics of middle-aged and elderly patients with stage III rectal adenocarcinoma

	Training cohort (1944)		Validation cohort (829)		Overall (2773)
Variable	Quantity	SCALE	Quantity	SCALE	Quantity	SCALE	P value
Age (yr)							0.596
45-62	1107	56.94%	456	55.01%	1563	56.36%
62-75	588	30.25%	258	31.12%	846	30.51%
> 75	249	12.81%	115	13.87%	364	13.13%
Race							0.425
Other	146	7.51%	66	7.96%	212	7.65%
White	1511	77.73%	656	79.13%	2167	78.15%
Black	287	14.76%	107	12.91%	394	14.21%
Sex							0.051
Female	794	40.84%	305	36.79%	1099	39.63%
Male	1150	59.16%	524	63.21%	1674	60.37%
Grade							0.859
I/II	1642	84.47%	698	84.20%	2340	84.39%
III/IV	302	15.53%	131	15.80%	433	15.61%
Site							0.692
Rectosigmoid Junction	660	33.95%	275	33.17%	935	33.72%
Rectum	1284	66.05%	554	66.83%	1838	66.28%
Stage							0.138
III A	199	10.24%	90	10.86%	289	10.42%
III B	1394	71.71%	615	74.19%	2009	72.45%
III C	351	18.06%	124	14.96%	475	17.13%
Tumor size							0.204
≤ 68	1626	83.64%	677	81.66%	2303	83.05%
> 68	318	16.36%	152	18.34%	470	16.95%
CEA							0.558
Low	1074	55.25%	468	56.45%	1542	55.61%
High	870	44.75%	361	43.55%	1231	44.39%
TD							0.473
Neg	1481	76.18%	621	74.91%	2102	75.80%
Pos	463	23.82%	208	25.09%	671	24.20%
CRM							0.409
Pos	354	18.21%	162	19.54%	516	18.61%
Neg	1590	81.79%	667	80.46%	2257	81.39%
PNI							0.197
Neg	1551	79.78%	679	81.91%	2230	80.42%
Pos	393	20.22%	150	18.09%	543	19.58%
pLN							0.152
0	508	26.13%	204	24.61%	712	25.68%
1-6	1212	62.35%	546	65.86%	1758	63.40%
> 6	224	11.52%	79	9.53%	303	10.93%
DLNs							0.241
≤ 26	1675	86.16%	728	87.82%	2403	86.66%
> 26	269	13.84%	101	12.18%	370	13.34%
LNR							0.246
0-0.12	1146	58.95%	477	57.54%	1623	58.53%
< 0.31	463	23.82%	221	26.66%	684	24.67%
> 0.31	335	17.23%	131	15.80%	466	16.80%

CEA: Carcinoembryonic antigen; TD: Tumor engraftment; CRM: Circumferential resection margin; PNI: Perineural invasion; pLN: Positive lymph nodes; DLNs: Examined lymph nodes; LNR: Lymph node-positive rate.